<DOC>
	<DOCNO>NCT00947336</DOCNO>
	<brief_summary>Background : Spontaneous bacterial peritonitis ( SBP ) serious complication patient cirrhosis ascites may occur despite antibiotic prophylaxis . Small bowel dysmotility bacterial overgrowth document related SBP . Aims : To investigate whether addition prebiotic plus probiotic ( synbiotics ) norfloxacin enhances efficacy norfloxacin prevention SBP high risk patient ascites . Methods : A prospective , double blind , randomize control trial conduct consecutive high-risk cirrhotic patient ascites either recovered episode SBP ( secondary prophylaxis ) never SBP high risk development SBP ( low ascitic fluid protein serum bilirubin â‰¥2.5 mg/dL ; primary prophylaxis ) . Norfloxacin 400 mg daily synbiotic capsule ( Streptococcus faecalis JPC 30 million , Clostridium butyricum 2 million , Bacillus mesentericus JPC 1 million , Lactobacillus sporogenes 50 million spore ) 2 t.i.d . ( group I ) norfloxacin 400 mg daily placebo ( group II ) give occurrence SBP within period 6 month ( primary endpoint ) side-effects therapy mortality ( secondary endpoint ) record . Every patient receive IV albumin maintain serum albumin level &gt; 3.2 g/dl . SBP treat intravenous antibiotic albumin .</brief_summary>
	<brief_title>Evaluation Safety &amp; Efficacy Synbiotic Incidence Recurrence Spontaneous Bacterial Peritonitis ( SBP ) Cirrhotics</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Norfloxacin</mesh_term>
	<criteria>Cirrhosis ascites one following : History least one episode SBP , Ascitic fluid protein less equal 1g/dL , Serum bilirubin equal 2.5 mg/dL Renal failure HCC Hepatic encephalopathy No consent</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>